If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Heroin from Afghanistan enters East Africa through the Swahili Coast, from the Indian Ocean. Many of the countries in East Africa affected by drug trafficking along the southern route have high poverty levels, poor governance and security challenges. This is exacerbated by ongoing tensions and conflicts within the region, making these states especially vulnerable to organised crime and the threat of exploitation that these criminal groups pose. Heroin seizures have indicated an increase in drug flow to the region, and further utilisation of the southern route. This has led to a growth in drug use and a rise in drug injecting in countries such as Mauritius, South Africa, Nigeria and Kenya. Opiates often reach East African on dhows, which are traditional trading ships originating in Arab and South Asian countries. Dhows used for smuggling have been caught carrying up to 1,000 kg of heroin. These East African countries do have their own consumer markets for drugs, but they are also heavily used as trans-shipment ports for routes which continue onwards e.g. to Europe.
It is used in the production of various organic peroxides and hydroperoxides. Dibenzoyl peroxide is a high-volume example. Peroxy acids, such as peracetic acid and meta-chloroperoxybenzoic acid also are produced using hydrogen peroxide. Hydrogen peroxide has been used for creating organic peroxide-based explosives, such as acetone peroxide. It is used as a Radical initiator in radical polymerization processes. Hydrogen peroxide reacts with certain di-esters, such as phenyl oxalate ester (cyalume), to produce chemiluminescence; this application is most commonly encountered in the form of glow sticks.
== Pharmacokinetics == The chemical is poorly soluble, and has only very limited penetration through intact skin. However, contact with body fluids produces free sulfadiazine which can then be systemically absorbed and distributed; it undergoes glucuronidation in the liver and is also excreted unaltered in urine. Only when applied to large-area (especially second- and third-degree) burns or other lesions is absorption into the body a problem.
Honey collection is an ancient activity, long preceding the honey bee's domestication; this traditional practice is known as honey hunting. A Mesolithic rock painting in a cave in Valencia, Spain, dating back at least 8,000 years, depicts two honey foragers collecting honey and honeycomb from a wild bees' nest. The figures are depicted carrying baskets or gourds, and using a ladder or series of ropes to reach the nest. Humans followed the greater honeyguide bird to wild beehives; this behavior may have evolved with early hominids. The oldest known honey remains were found in Georgia during the construction of the Baku–Tbilisi–Ceyhan pipeline: archaeologists found honey remains on the inner surface of clay vessels unearthed in an ancient tomb, dating back between 4,700 and 5,500 years. In ancient Georgia, several types of honey were buried with a person for journeys into the afterlife, including linden, berry, and meadow-flower varieties. The first written records of beekeeping are from ancient Egypt, where honey was used to sweeten cakes, biscuits, and other foods and as a base for unguents in Egyptian hieroglyphs. The dead were often buried in or with honey in Egypt, Mesopotamia and other regions. Bees were kept at temples to produce honey for temple offerings, mummification and other uses. In southern Illyria (present day Albania), the Iron Age Illyrian tribe of the Abroi were known for preparing mead, a wine from honey, as documented by Hecataeus of Miletus in the 6th century BCE. In ancient Greece, honey was produced from the Archaic to the Hellenistic periods.
Sources: en.wikipedia.org
Comatose patients may aspirate their vomit (resulting in vomitus in the lungs, which may cause "drowning" and later pneumonia if survived). CNS depression and impaired motor coordination along with poor judgment increase the likelihood of accidental injury occurring. It is estimated that about one-third of alcohol-related deaths are due to accidents and another 14% are from intentional injury. In addition to respiratory failure and accidents caused by its effects on the central nervous system, alcohol causes significant metabolic derangements. Hypoglycaemia occurs due to ethanol's inhibition of gluconeogenesis, especially in children, and may cause lactic acidosis, ketoacidosis, and acute kidney injury. Metabolic acidosis is compounded by respiratory failure. Patients may also present with hypothermia.
== Future == The expansion of the genetic code is still in its infancy. Current methodology uses only one non-standard amino acid at the time, whereas ideally multiple could be used. In fact, the group of Jason Chin has recently broken the record for a genetically recoded E. coli strain that can simultaneously incorporate up to 4 unnatural amino acids. Moreover, there has been development in software that allows combination of orthogonal ribosomes and unnatural tRNA/RS pairs in order to improve protein yield and fidelity.
Many returning coalition soldiers reported illnesses following their action in the war, a phenomenon known as Gulf War syndrome (GWS) or Gulf War illness (GWI). Common symptoms reported are chronic fatigue, fibromyalgia, and gastrointestinal disorder. There has been widespread speculation and disagreement about the causes of the illness and the possibly related birth defects. Researchers found that infants born to male veterans of the 1991 war had higher rates of two types of heart valve defects. Some children born after the war to Gulf War veterans had a certain kidney defect that was not found in Gulf War veterans' children born before the war. Researchers have said that they did not have enough information to link birth defects with exposure to toxic substances. In 1994, the US Senate Committee on Banking, Housing, and Urban Affairs with Respect to Export Administration published a report entitled, "U.S. Chemical and Biological Warfare-Related Dual Use Exports to Iraq and their Possible Impact on the Health Consequences of the Gulf War". This publication, called the Riegle Report, summarized testimony this committee had received establishing that the U.S. had in the 1980s supplied Saddam Hussein with chemical and biological warfare technology, that Saddam had used such chemical weapons against Iran and his own native Kurds, and possibly against U.S. soldiers as well, plausibly contributing to the GWS. A 2022 study by Robert W. Haley of the University of Texas Southwestern Medical Center, et al., of 1,016 U.S.
Sources: en.wikipedia.org
In many histological preparations of the submandibular gland, the serous acinar cells located in the hybrid seromucous acini are pushed out from between the mucous acinar cells, and appear as crescent-shaped demilunes located at the back of the acini. This fixation artifact can be avoided by rapid-freezing fixation.
== Artificial de-excitation == 180mTa can be forced to release its energy by X-rays. This was predicted theoretically in 1988 by C. B. Collins, although at that time this de-excitation mechanism had never been observed. This was observed in 180mTa by resonant photo-excitation of intermediate high levels of this nucleus (E ≈ 1 MeV), in 1999 by Belic and co-workers in the Stuttgart nuclear physics group. 178m272Hf is another reasonably stable nuclear isomer, with a half-life of 31 years and a remarkably high excitation energy for that life. In its natural decay, 2.45 MeV is released as gamma rays. As with 180mTa, it is thought that 178m2Hf can be stimulated into releasing its energy. Due to this, the substance has been studied as a possible source for gamma-ray lasers, and reports have indicated that the energy could be released very quickly, so that 178m2Hf can produce extremely high powers (on the order of exawatts). It was supposedly detected experimentally in the 2000s, but it was controversial and not independently confirmed. Other isomers have also been investigated as possible media for gamma-ray stimulated emission.
=== Research === G-CSF when given early after exposure to radiation may improve white blood cell counts, and is stockpiled for use in radiation incidents. Mesoblast planned in 2004 to use G-CSF to treat heart degeneration by injecting it into the blood-stream, plus SDF (stromal cell-derived factor) directly to the heart. G-CSF has been shown to reduce inflammation, reduce amyloid beta burden, and reverse cognitive impairment in a mouse model of Alzheimer's disease. Due to its neuroprotective properties, G-CSF is currently under investigation for cerebral ischemia in a clinical phase IIb and several clinical pilot studies are published for other neurological disease such as amyotrophic lateral sclerosis A combination of human G-CSF and cord blood cells has been shown to reduce impairment from chronic traumatic brain injury in rats.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.